Tamsulosin HCl (MR) & Dutasteride Tablets — Tablets
WHO-GMP Certified Commercial Pack · Product Code: AKP-352

Tamsulosin HCl (MR) & Dutasteride Tablets

Formulation Overview: Synergistic men's urology formulation combining modified-release tamsulosin 0.4 mg smooth-muscle relaxation with dual type-1/type-2 5-alpha-reductase inhibition (dutasteride 0.5 mg). Formulated with Tamsulosin HCl (MR) 0.4 mg + Dutasteride 0.5 mg (0.4 mg (MR) + 0.5 mg) in Modified-Release Combo Tablets dosage form under Sexual Wellness Medication, manufactured to IP / BP / USP Compendial standards and supplied in 10 x 10 Alu-Alu / Blister Pack with complete eCTD/ACTD regulatory dossiers, Zone IVb stability, and batch CoA for African NRAs (NAFDAC, PPB, SAHPRA, TMDA, FDA Ghana) and global tenders.
Item Code (SKU)AKP-352
Catalog ReferenceAKP-352 · SN 352
Therapeutic SectorSexual Wellness Medication
Dosage FormModified-Release Combo Tablets
Active IngredientTamsulosin HCl (MR) 0.4 mg + Dutasteride 0.5 mg
Strength / Purity0.4 mg (MR) + 0.5 mg
Clinical IndicationSymptomatic benign prostatic hyperplasia (BPH) in men with enlarged prostate gland and acute urinary retention risk
Specification StandardIP / BP / USP Compendial
Packaging Format10 x 10 Alu-Alu / Blister Pack
Shelf Life24–36 Months
Storage ConditionsStore below 25°C in a dry place, protect from light and moisture
Minimum Order Quantity1000 Packs
Regulatory / Analytical DocsFull eCTD / ACTD Modules 1–5 + Zone IVb Stability Available
African & Global NRA ReadinessNAFDAC (Nigeria), PPB (Kenya), SAHPRA (SA), TMDA (Tanzania), FDA Ghana, AIRP, ARP, EFDA
Stock AvailabilityIn Stock · Immediate Commercial Dispatch
Supply StatusCommercial Export Ready

Related Tablets & Sexual Wellness Medication